TAGline October 2023
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
HCV Elimination Among People Living with and at Risk of HIV: Challenges and Opportunities
Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.
Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
Letter to Dr. Jeanne Marazzo, New Director NIAID
We're excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).
TAG Mourns the Loss of Dr. Stephaun Elite Wallace
TAG extends our deepest condolences to the family, friends and loved ones of Dr. Stephaun Elite Wallace, PhD, MS. Dr. Wallace was a treasure to all who knew and worked with him, and his legacy of mentorship and community engagement in the HIV research landscape will be felt for generations.
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...
Open Letter: Urgent Action Necessary for Equitable Access to Bedaquiline in All Countries with High Burdens of TB, MDR-TB, and TB/HIV
TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company...
An Activist’s Protocol Review Toolkit
An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.
TAG Remarks Delivered at Multistakeholder Hearings, May, 2023
TAG prepared these remarks to deliver at multistakeholder hearings on health held on May 8 and 9, 2023, at the United Nations Headquarters in New York City.
Nitrosamines and TB Medicines Information Note and Patient FAQs
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…